Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Anti-cancer effect of pristimerin by inhibition of HIF-1α involves the SPHK-1 pathway in hypoxic prostate cancer cells

Fig. 2

Pristimerin exerts significant inhibition of SPHK-1 in hypoxic PC-3 cells. a Cells were treated with or without pristimerin (0.5 and 1 μM) under normoxia and hypoxia for 4 h. Western blotting was performed to determine SPHK-1 expression. b Quantitative protein levels are shown. The results are expressed as means ± SD for the triplicate. *** p <0.001 compared with hypoxia control. c Pristimerin inhibits hypoxia-induced HIF-1α and SPHK-1 accumulation in PC-3 cells under hypoxia in a time-dependent manner. Cells were treated with 1 μM pristimerin for 0, 0.5, 4, 6, or 8 h under hypoxia. Western blotting was performed to determine HIF-1α and SPHK-1 expressions in PC-3 cells. d Quantitative protein levels are shown (SPHK-1). The results are expressed as means ± SD for the duplicate. * p <0.05 compared with hypoxia control at each time point e Quantitative protein levels are shown (HIF-1α). The results are expressed as means ± SD for the duplicate. * p <0.05 and ** p <0.01 compared with hypoxia control at each time point

Back to article page